FORMULATION, DEVELOPMENT AND IN VITRO EVALUATION BEZAFIBRATE FAST DISSOLVING TABLETSg[p[pv

Fuente: Zenodo
Guardado en:
Detalles Bibliográficos
Autor principal: Dr. P. Perumal, S. Selvaraj*, K. Manimekala
Formato: Recurso digital
Lenguaje:inglés
Publicado: Zenodo 2026
Acceso en línea:
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
_version_ 1866901351272808448
author Dr. P. Perumal, S. Selvaraj*, K. Manimekala
author_facet Dr. P. Perumal, S. Selvaraj*, K. Manimekala
contents <p><span>This study aimed to formulate, develop, and evaluate fast-dissolving tablets of bezafibrate using the solid dispersion method. The formulation process focused on enhancing the dissolution rate and bioavailability of bezafibrate, a poorly water-soluble drug. Precompression parameters such as thickness, diameter, hardness, friability, drug content, and weight variation were optimized to ensure the quality and uniformity of the tablets. In vitro evaluation involved assessing dispersion time, wetting time, and dissolution profiles over a three-month period to determine stability under different storage conditions. The findings suggest that the developed bezafibrate fast-dissolving tablets hold promise for improved drug delivery and patient compliance, offering valuable insights into their formulation and performance.</span></p>
format Recurso digital
id zenodo_https___doi_org_10_5281_zenodo_19627463
institution Zenodo
language eng
publishDate 2026
publisher Zenodo
record_format zenodo
spellingShingle FORMULATION, DEVELOPMENT AND IN VITRO EVALUATION BEZAFIBRATE FAST DISSOLVING TABLETSg[p[pv
Dr. P. Perumal, S. Selvaraj*, K. Manimekala
<p><span>This study aimed to formulate, develop, and evaluate fast-dissolving tablets of bezafibrate using the solid dispersion method. The formulation process focused on enhancing the dissolution rate and bioavailability of bezafibrate, a poorly water-soluble drug. Precompression parameters such as thickness, diameter, hardness, friability, drug content, and weight variation were optimized to ensure the quality and uniformity of the tablets. In vitro evaluation involved assessing dispersion time, wetting time, and dissolution profiles over a three-month period to determine stability under different storage conditions. The findings suggest that the developed bezafibrate fast-dissolving tablets hold promise for improved drug delivery and patient compliance, offering valuable insights into their formulation and performance.</span></p>
title FORMULATION, DEVELOPMENT AND IN VITRO EVALUATION BEZAFIBRATE FAST DISSOLVING TABLETSg[p[pv
url https://doi.org/10.5281/zenodo.19627463